K
Kathy Shores-Wilson
Researcher at University of Texas Southwestern Medical Center
Publications - 48
Citations - 10868
Kathy Shores-Wilson is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Major depressive disorder & STAR*D. The author has an hindex of 32, co-authored 47 publications receiving 10045 citations. Previous affiliations of Kathy Shores-Wilson include University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice
Madhukar H. Trivedi,A. John Rush,Stephen R. Wisniewski,Andrew A. Nierenberg,Diane Warden,Louise Ritz,Grayson Norquist,Robert H Howland,Barry D. Lebowitz,Patrick J. McGrath,Kathy Shores-Wilson,Melanie M. Biggs,Goundappa K. Balasubramani,Maurizio Fava +13 more
TL;DR: The response and remission rates in this highly generalizable sample with substantial axis I and axis III comorbidity closely resemble those seen in 8-week efficacy trials.
Journal ArticleDOI
Sequenced treatment alternatives to relieve depression (STAR * D): rationale and design
A. John Rush,Maurizio Fava,Stephen R. Wisniewski,Philip W. Lavori,Madhukar H. Trivedi,Harold A. Sackeim,Michael E. Thase,Andrew A. Nierenberg,Frederic M. Quitkin,T. Michael Kashner,David J. Kupfer,Jerrold F. Rosenbaum,Jonathan E. Alpert,Jonathan W. Stewart,Patrick J. McGrath,Melanie M. Biggs,Kathy Shores-Wilson,Barry D. Lebowitz,Louise Ritz,George Niederehe +19 more
TL;DR: STAR*D as discussed by the authors is a multisite, prospective, randomized, multistep clinical trial of outpatients with nonpsychotic major depressive disorder, which compared various treatment options for those who do not attain a satisfactory response with citalopram, a selective serotonin reuptake inhibitor antidepressant.
Journal ArticleDOI
Medication Augmentation after the Failure of Ssris for Depression
Madhukar H. Trivedi,Maurizio Fava,Stephen R. Wisniewski,Michael E. Thase,Frederick M. Quitkin,Diane Warden,Louise Ritz,Andrew A. Nierenberg,Barry D. Lebowitz,Melanie M. Biggs,James F. Luther,Kathy Shores-Wilson,A. John Rush +12 more
TL;DR: Augmentation of citalopram with either sustained-release bupropion or buspirone appears to be useful in actual clinical settings, including a greater reduction in the number and severity of symptoms and fewer side effects and adverse events.
Journal ArticleDOI
Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Jonathan W. Stewart,Andrew A. Nierenberg,Michael E. Thase,Louise Ritz,Melanie M. Biggs,Diane Warden,James F. Luther,Kathy Shores-Wilson,George Niederehe,Maurizio Fava +12 more
TL;DR: After unsuccessful treatment with an SSRI, approximately one in four patients had a remission of symptoms after switching to another antidepressant, suggesting any one of the medications in the study provided a reasonable second-step choice for patients with depression.
Journal ArticleDOI
The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation.
Madhukar H. Trivedi,A. J. Rush,A. J. Rush,H. M. Ibrahim,H. M. Ibrahim,Thomas J. Carmody,M. M. Biggs,M. M. Biggs,Trisha Suppes,Trisha Suppes,ML Crismon,ML Crismon,Kathy Shores-Wilson,Kathy Shores-Wilson,M. G. Toprac,M. G. Toprac,E. B. Dennehy,E. B. Dennehy,B. Witte,B. Witte,T. M. Kashner,T. M. Kashner +21 more
TL;DR: The QIDS-SR16 andQIDS-C16, as well as the longer 30-item versions, have highly acceptable psychometric properties and are treatment sensitive measures of symptom severity in depression.